In line, we also show a?higher seroprevalence of 16
In line, we also show a?higher seroprevalence of 16.6% in the whole area of Landeck and 33.0% among blood donors living in Ischgl, whereas seroprevalence in other districts of Tyrol was substantially lower. area Landeck (16.6%, angiotensin converting enzyme, angiotensin receptor blockers Open in a separate window Fig. 4 Seroprevalence of SARS-CoV?2 IgG antibodies in the Tyrolean blood donor cohort relating to self-reported travel history. The analysis of travel to hotspots excluded participants already living in the respective areas. The region Hinteres Zillertal included the municipalities Finkenberg, Tux, Schwendau, Mayrhofen, Brandenberg, Ramsau, Heinzenberg, and Hippach. The region St. Anton/Arlberg included the municipalities St. Anton, Pettneu, Strengen and Flirsch. The questionnaire resolved travel history to other federal states starting from 1?December 2019, whereas travels L-690330 to countries abroad were addressed for the preceding six months Second, we analyzed whether seroprevalence differed by self-reported travel to other Austrian federal claims since 1?December 2019. Seroprevalence was 3.8% among the 1429?participants who also travelled to other Austrian federal government claims and 2.8% among the 3916?participants who did not, corresponding to an odds percentage for seropositivity of 1 1.39 (95% CI 1.00C1.93, P?=?0.052). Results for the individual federal claims of Austria are demonstrated in Fig.?4. While odds to be seropositive were elevated among participants with a?recent travel L-690330 to Carinthia (OR: 2.07, 95% CI EPHB4 1.22C3.51, P?0.007), they did not differ significantly by travel history to other federal claims. Third, we evaluated whether participants travelled abroad in the 6 months preceding the blood donation. Seroprevalence was 6.4% among the 467?participants reported to have travelled abroad and 2.8% among the 4878?participants who did not, corresponding to an odds percentage for seropositivity of 2.41 (95% CI 1.61C3.63, P?0.001). The most common travel destination was Germany, associated with an odds percentage of 3.55 (95% CI 1.92C6.57, P?0.001) of being seropositive (Fig.?4). Seroprevalence relating to self-reported medication intake To evaluate if the intake of certain medications was associated with higher or lower prevalence, we assessed medication intake categorized by predefined different drug classes. When we compared seroprevalence according to intake of medication, we observed no significant differences by any of the drug classes angiotensin converting enzyme inhibitors/angiotensin receptor blockers, other antihypertensive drugs, analgesics, low-dose acetylsalicylic acid, lipid lowering brokers, thyroid hormones, anti-allergic drugs and hormone preparations (i.e.?hormonal contraception, postmenopausal hormone replacement therapy, all P?>?0.05) (Fig.?4). Assessment of self-reported symptoms in a?subset of the study populace We conducted a?telephone survey to assess self-reported symptoms among 123?participants who were seropositive and 122?participants who were seronegative and had suspected having had an infection or had a?laboratory confirmed SARS-CoV?2 contamination in the past. The telephone survey covered the symptoms fever (>?38?C), cough, sore throat, limb pain, shortness of breath, dyspnea, headache, vomiting/nausea, diarrhea, anosmia and ageusia. Of them, L-690330 anosmia (OR?=?2.49, 95% CI 1.32C4.68, P?=?0.005) and ageusia (OR?=?2.76, 95% CI 1.54C4.92, P?=?0.001) were linked to higher odds L-690330 of being seropositive, whereas cough (OR?=?0.39, 95% CI 0.23C0.67, P?=?0.001) and limb pain (OR?=?0.51, 95% CI 0.30C0.86, P?=?0.011) were linked to lower odds of being seropositive (Fig.?6). Out of the 123 seropositive participants, 30 reported none of the aforementioned symptoms (24.4%). Open in a separate windows Fig. 6 Seroprevalence of SARS-CoV?2 IgG antibodies in the Tyrolean blood donor cohort according to self-reported symptoms Discussion The present study reports around the seroprevalence of SARS-CoV?2 antibodies in 5345?healthy individuals recruited at local blood donor sessions in the federal state of Tyrol, Austria. Our study shows that, in summer time 2020, seroprevalence was 3.1% and therefore approximately five occasions higher than expected based on the number of cases identified through the state-wide testing program in place at that time. A?comparable gap in the detection of SARS-CoV-2?cases at the start of the pandemic in spring 2020 has been previously shown by a?study.